Literature DB >> 8111384

Missense mutations impair intracellular processing of fibrillin and microfibril assembly in Marfan syndrome.

T Aoyama1, K Tynan, H C Dietz, U Francke, H Furthmayr.   

Abstract

Dermal fibroblasts from nine Marfan syndrome patients with missense mutations in the fibrillin-1 gene (FBN1) produced nearly normal amounts of fibrillin as determined by quantitative pulse-chase experiments. However, six of the seven mutations involving substitutions of highly conserved cysteine residues exhibited lower rates of intracellular transport and secretion. This effect is likely due to improper folding, since intracellular fibrillin processing was also affected by the reducing agent dithiothreitol. Normal secretion patterns were seen in three mutations that either change the conformation of EGF-like domains or change consensus amino acids required for Ca(++)-binding. In all nine fibroblasts strains, however, the deposition of fibrillin in the extracellular matrix was reduced to 50% of normal in two and to less than 30% in seven of the nine samples studied. The protein alterations caused by these missense mutations are associated with moderate to severe features of Marfan syndrome and a dominant negative mechanism is suggested to play a major role in their pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8111384     DOI: 10.1093/hmg/2.12.2135

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  22 in total

Review 1.  The molecular genetics of Marfan syndrome and related microfibrillopathies.

Authors:  P N Robinson; M Godfrey
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

2.  Familial occurrence of typical and severe lethal congenital contractural arachnodactyly caused by missplicing of exon 34 of fibrillin-2.

Authors:  M Wang; C L Clericuzio; M Godfrey
Journal:  Am J Hum Genet       Date:  1996-11       Impact factor: 11.025

3.  Double mutant fibrillin-1 (FBN1) allele in a patient with neonatal Marfan syndrome.

Authors:  M Wang; P Kishnani; M Decker-Phillips; S G Kahler; Y T Chen; M Godfrey
Journal:  J Med Genet       Date:  1996-09       Impact factor: 6.318

4.  Intragenic multi-exon deletion in the FBN1 gene in a child with mildly dilated aortic sinus: a retrotransposal event.

Authors:  Maggie Brett; George Korovesis; Angeline H M Lai; Eileen C P Lim; Ene-Choo Tan
Journal:  J Hum Genet       Date:  2017-03-23       Impact factor: 3.172

Review 5.  The molecular genetics of Marfan syndrome and related disorders.

Authors:  P N Robinson; E Arteaga-Solis; C Baldock; G Collod-Béroud; P Booms; A De Paepe; H C Dietz; G Guo; P A Handford; D P Judge; C M Kielty; B Loeys; D M Milewicz; A Ney; F Ramirez; D P Reinhardt; K Tiedemann; P Whiteman; M Godfrey
Journal:  J Med Genet       Date:  2006-03-29       Impact factor: 6.318

6.  Early fibrillin-1 assembly monitored through a modifiable recombinant cell approach.

Authors:  Dirk Hubmacher; Eric Bergeron; Christine Fagotto-Kaufmann; Lynn Y Sakai; Dieter P Reinhardt
Journal:  Biomacromolecules       Date:  2014-03-07       Impact factor: 6.988

7.  Determination of the molecular basis of Marfan syndrome: a growth industry.

Authors:  Peter H Byers
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

Review 8.  Biogenesis and function of fibrillin assemblies.

Authors:  Francesco Ramirez; Lynn Y Sakai
Journal:  Cell Tissue Res       Date:  2009-06-10       Impact factor: 5.249

9.  Marfan syndrome: fibrillin expression and microfibrillar abnormalities in a family with predominant ocular defects.

Authors:  C M Kielty; S J Davies; J E Phillips; C J Jones; C A Shuttleworth; S J Charles
Journal:  J Med Genet       Date:  1995-01       Impact factor: 6.318

10.  Quantitative differences in biosynthesis and extracellular deposition of fibrillin in cultured fibroblasts distinguish five groups of Marfan syndrome patients and suggest distinct pathogenetic mechanisms.

Authors:  T Aoyama; U Francke; H C Dietz; H Furthmayr
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.